Cannabics Pharmaceuticals Inc., an international leader developing cancer-related cannabinoid-based drugs, headquartered in Maryland, United States, announced on Wednesday, July 07, that it had welcomed Dr. Inbar Maymon-Pomeranchik company’s Board of directors table as an Independent Director.
Dr. Maymon-Pomeranchik is a highly trained professional with expertise in molecular and genetic research. He holds a Ph.D. from Hebrew University and has approximately 20 years of executive-level experience in biotechnology sciences with particular professional expertise in the global medical cannabis industry. Dr. Maymon-Pomeranchik serves as a board member for multiple public firms and companies.
She is particularly thrilled with its plans to seek FDA approval for its expanding pipeline of promising drug candidates.The technology-driven drug development company has its R&D facility set up in Israel. The Cannabics Pharmaceutical facility in Israel is licensed by the Ministry of Health, permitting them to conduct science and clinical research on Cannabics formulations.